Abstract
A review of the historic use of cardiac biomarkers for evaluation of coronary syndromes creates a twisting network of timelines and advances that illustrate the scientific method of precision medicine. Publication of clinical practice guidelines have established milestones along those timelines and the recent consensus recommendations for use of cardiac troponins (cTn) (1) exists in the context of previous accomplishments and the challenges ahead.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
